World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02324049
Date of registration: 15/12/2014
Prospective Registration: Yes
Primary sponsor: Alexion Pharmaceuticals
Public title: Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
Scientific title: A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Date of first enrolment: January 22, 2015
Target sample size: 11
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02324049
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 1/Phase 2
Countries of recruitment
Spain United Kingdom United States
Contacts
Key inclusion & exclusion criteria

Key Inclusion Criteria:

- A participant was greater than or equal to 2 years of age but less than 12 years of
age at the time of informed consent.

- Definitive diagnosis of MPS IIIB.

- Documented developmental delay.

Key Exclusion Criteria:

- Received treatment with gene therapy at any time.

- Previous hematopoietic stem cell or bone marrow transplant.

- Had any internal or non-removable external metal items that presented a safety risk
for study assessments that utilized magnetic fields, or any other medical condition or
circumstance in which magnetic resonance imaging was contraindicated according to
local institutional policy.

- Known hypersensitivity to eggs.



Age minimum: 2 Years
Age maximum: 12 Years
Gender: All
Health Condition(s) or Problem(s) studied
Mucopolysaccharidosis IIIB
Intervention(s)
Drug: SBC-103
Primary Outcome(s)
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) [Time Frame: Baseline to Week 142]
Secondary Outcome(s)
Secondary ID(s)
NGLU-CL02
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 12/07/2018
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02324049
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey